Changing the Face of Oral Cancer Testing
Wisdom Bioscience offers a state-of-the-art oral cancer test that can detect early signs of this devastating disease. Our advanced diagnostic technology provides accurate and reliable results.
A new approach to Oral Cancer Testing
Our team of experienced scientists has developed a state-of-the-art test to provide an early indication of elevated risk of this disease.
Welcome to Wisdom Bioscience
Cancer Testing
Cancer testing remains the most important lever for reducing oncology patient burden, find it early, treat it earlier.
Existing cancer testing can be difficult to access due to high cost, ineffective delivery, and uncertain reimbursement or funding.
Oral Cancer
For oral cancer existing tools are either incapable, inaccurate human inspection, or don’t incentivize adoption and utilization through high cost to dental providers.
Wisdom Bioscience's approach will enable the broad adoption of gold-standard molecular testing for oral cancer, with little or no cost to Dentists or Patients.
Our Approach
A diiferentiated, IP protected, approach that utilizes existing biomarkers and technology. The company is led by an experienced team, each with more than 25 years of healthcare, laboratory operations, and molecular diagnostic development.
Wisdom Bioscience Leadership Team
Hayden Jeffreys - Chief Executive Officer
Hayden Jeffreys - Chief Executive Officer
Hayden Jeffreys - Chief Executive Officer
25 years’ clinical diagnostics industry experience including public and private markets, specializing in molecular diagnostics, including:
- NED of Calbiotech Inc, Invitron & Advisor to Biolyph Inc
- Former COO of Yourgene Health & Cambridge Epigenetix
- CEO of Erba Diagnostics Inc & Head of BD and Strategy at ERBA Group.
Dr. Aditya Rajagopal - Executive Chair
Hayden Jeffreys - Chief Executive Officer
Hayden Jeffreys - Chief Executive Officer
Executive Chairman of Wisdom Biosciences
- CEO of EspertoMedical, a Caltech spin-out building physiometricmonitors.
- Founder and Chairman of ChromaCode, a revenue stage oncology Dx Company
- Part-time faculty at Caltech and USC, formerly venture partner at ND Capital
Si Hyun Kim - Chief Scientific Officer
Si Hyun Kim - Chief Scientific Officer
Si Hyun Kim - Chief Scientific Officer
Experienced scientific leader, with more than 15 years of expertise in molecular biology, assay and technology development.
Scientist, Genentech
- Barcoded NGS development
- Outsourcing Management
Staff Scientist, Q2 Solutions
- Genomic assay development
- Laboratory automation
Prof. Scott E Fraser - Senior Advisor
Si Hyun Kim - Chief Scientific Officer
Si Hyun Kim - Chief Scientific Officer
Professor Scott E. Fraser has a long-standing commitment to quantitative biology, applying the tools of chemistry, engineering, and physics to problems in fields ranging from developmental biology to medicine.
He has served on the faculties of UC Irvine, Caltech & USC, and now is the Vice President of the CZI, one of the largest science philanthropies.